ExonHit buys RedPath in $32M diagnostics play

France's ExonHit Therapeutics has established a new beachhead in the U.S. molecular diagnostics market with its newly announced deal to buy Pittsburgh-based RedPath Integrated Pathology for $22.5 million in cash and stock plus $9.5 million in sales milestones. RedPath CEO Mark Myslinski says the buyout will pump fresh funds into the company, which sells a molecular diagnostic test for pancreatic cancer. Myslinski is poised to become the expanded company's chief of global molecular...